ArticleFluids and barriers of the CNS2026
Plasma biomarkers of Alzheimer's disease and their association with disproportionately enlarged subarachnoid space hydrocephalus.
Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundIndividuals with both Alzheimer’s Disease (AD) and cerebrospinal fluid (CSF) dynamics disorders, such as idiopathic normal-pressure hydrocephalus (iNPH), exhibit reduced CSF Aβ42 levels, complicating the interpretation of AD biomarkers. However, the influence of CSF dynamics on blood-based AD biomarkers remains unclear. This study investigated whether immunoprecipitation mass spectrometry (IP-MS)-based AD plasma biomarkers were associated with disproportionately enlarged subarachnoid space hydrocephalus (DESH) on MRI.
methodThis retrospective, cross-sectional study included 509 participants from the Mayo Clinic Study of Aging who underwent MRI, [¹¹C] Pittsburgh compound B (Aβ) PET imaging, and plasma assessments of phosphorylated tau 217 (p-Tau 217), Aβ40, and Aβ42. Age-adjusted logistic regression analyses were conducted to evaluate whether abnormal levels of p-Tau 217, %p-Tau 217 (ratio of phosphorylated to non-phosphorylated tau × 100%), Aβ42, or the Aβ42/40 ratio were associated with DESH, as identified by a previously validated automated algorithm. In addition, combinations of binary amyloid PET and plasma biomarkers to create 4 categories were tested for an association with DESH as a sensitivity analysis.
resultAverage age was 72.2 (8.8), with 54% male participants, and 30% were APOE4 carriers. Thirty-two participants (6.3%) were classified as having DESH. Abnormal (low) plasma Aβ42 (OR: 2.56 [95% CI: 1.19, 5.74]) and abnormal (high) p-tau217 (OR: 2.74 [95% CI: 1.09, 7.85]) were associated with DESH, but not the respective ratios of Aβ42/40 (OR: 1.95 [95% CI: 0.94, 4.17]) or %p-tau (OR: 1.82 [95% CI: 0.74, 4.20]). Analysis of the combined variables (amyloid PET and plasma biomarkers) demonstrated that an association with DESH was observed only in participants who were abnormal on both measures, compared with participants who were negative on both plasma biomarkers and PET. This association was attenuated when biomarker ratios were used.
conclusionThe observed association between abnormal plasma biomarker levels and DESH aligns with previous CSF studies and can be mitigated by utilizing the biomarker ratios. However, further validation is needed in populations with more severe CSF flow abnormalities to better understand the role of plasma biomarkers in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.